 Olga Taraschenko
Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Seizures | 14 | 2025 | 477 | 5.150 |
Why?
| | Status Epilepticus | 11 | 2026 | 67 | 3.610 |
Why?
| | Epilepsy | 9 | 2024 | 387 | 3.240 |
Why?
| | Drug Resistant Epilepsy | 13 | 2026 | 137 | 3.130 |
Why?
| | Electroencephalography | 18 | 2025 | 551 | 3.130 |
Why?
| | Anticonvulsants | 7 | 2024 | 242 | 2.500 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 3 | 2024 | 21 | 2.210 |
Why?
| | Ibogaine | 7 | 2011 | 8 | 1.670 |
Why?
| | Neurology | 2 | 2022 | 114 | 1.230 |
Why?
| | Encephalitis | 3 | 2026 | 142 | 0.870 |
Why?
| | Physician Executives | 1 | 2024 | 28 | 0.830 |
Why?
| | Maze Learning | 1 | 2024 | 104 | 0.830 |
Why?
| | Patient Handoff | 1 | 2024 | 43 | 0.800 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2024 | 116 | 0.770 |
Why?
| | Coma | 1 | 2023 | 38 | 0.760 |
Why?
| | Memory Disorders | 1 | 2024 | 194 | 0.760 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 2 | 2024 | 228 | 0.760 |
Why?
| | Hemispherectomy | 1 | 2022 | 3 | 0.750 |
Why?
| | Memory | 1 | 2025 | 296 | 0.750 |
Why?
| | Neurogenesis | 1 | 2024 | 157 | 0.730 |
Why?
| | Brain | 8 | 2025 | 2941 | 0.720 |
Why?
| | Language | 1 | 2025 | 323 | 0.710 |
Why?
| | Emergencies | 1 | 2022 | 176 | 0.690 |
Why?
| | Movement Disorders | 1 | 2022 | 70 | 0.690 |
Why?
| | Epilepsy, Generalized | 1 | 2021 | 20 | 0.690 |
Why?
| | Amnesia, Anterograde | 1 | 2021 | 7 | 0.680 |
Why?
| | Hippocampus | 2 | 2024 | 967 | 0.660 |
Why?
| | Information Technology | 1 | 2020 | 3 | 0.650 |
Why?
| | Receptors, Interleukin-1 | 1 | 2021 | 214 | 0.620 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2021 | 254 | 0.610 |
Why?
| | Brain Diseases | 1 | 2021 | 153 | 0.610 |
Why?
| | Anti-Obesity Agents | 2 | 2010 | 66 | 0.610 |
Why?
| | Autoantibodies | 3 | 2024 | 1504 | 0.590 |
Why?
| | Central Nervous System Neoplasms | 1 | 2021 | 174 | 0.570 |
Why?
| | Psychophysiologic Disorders | 1 | 2018 | 11 | 0.560 |
Why?
| | Nicotinic Antagonists | 2 | 2011 | 37 | 0.560 |
Why?
| | Ambulatory Care Facilities | 1 | 2021 | 266 | 0.550 |
Why?
| | Neuroimaging | 3 | 2024 | 292 | 0.550 |
Why?
| | Time-to-Treatment | 1 | 2020 | 245 | 0.530 |
Why?
| | Narcotics | 3 | 2007 | 58 | 0.520 |
Why?
| | Anticoagulants | 2 | 2020 | 725 | 0.500 |
Why?
| | Morphine | 3 | 2007 | 171 | 0.480 |
Why?
| | Ambulatory Care | 1 | 2021 | 603 | 0.470 |
Why?
| | Automobile Driving | 1 | 2018 | 157 | 0.460 |
Why?
| | Male | 28 | 2026 | 72416 | 0.440 |
Why?
| | Wallerian Degeneration | 1 | 2014 | 4 | 0.440 |
Why?
| | Humans | 39 | 2026 | 144981 | 0.440 |
Why?
| | Epilepsies, Partial | 2 | 2026 | 63 | 0.430 |
Why?
| | Software | 1 | 2020 | 692 | 0.430 |
Why?
| | Infarction, Middle Cerebral Artery | 1 | 2014 | 42 | 0.430 |
Why?
| | Tick Paralysis | 1 | 2014 | 1 | 0.420 |
Why?
| | Rats, Sprague-Dawley | 12 | 2011 | 2540 | 0.410 |
Why?
| | Brain Stem Infarctions | 1 | 2013 | 1 | 0.410 |
Why?
| | Electrocorticography | 2 | 2025 | 20 | 0.390 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2013 | 47 | 0.390 |
Why?
| | Conditioning, Operant | 2 | 2010 | 99 | 0.370 |
Why?
| | Nucleus Accumbens | 3 | 2011 | 135 | 0.370 |
Why?
| | Obesity | 3 | 2011 | 3082 | 0.360 |
Why?
| | Mice, Inbred C57BL | 5 | 2026 | 5997 | 0.360 |
Why?
| | Female | 30 | 2026 | 78387 | 0.350 |
Why?
| | Astrocytes | 2 | 2026 | 224 | 0.350 |
Why?
| | Adult | 17 | 2026 | 40511 | 0.340 |
Why?
| | Telemedicine | 1 | 2021 | 949 | 0.340 |
Why?
| | Dopamine | 3 | 2011 | 289 | 0.340 |
Why?
| | Rats | 12 | 2011 | 5614 | 0.330 |
Why?
| | Animals | 19 | 2026 | 38111 | 0.330 |
Why?
| | Middle Aged | 17 | 2026 | 35937 | 0.330 |
Why?
| | Sucrase | 1 | 2010 | 2 | 0.330 |
Why?
| | Disease Models, Animal | 5 | 2026 | 4569 | 0.330 |
Why?
| | Pedunculopontine Tegmental Nucleus | 2 | 2008 | 6 | 0.330 |
Why?
| | Signal Transduction | 1 | 2024 | 5233 | 0.320 |
Why?
| | Acetylcholine | 2 | 2008 | 206 | 0.310 |
Why?
| | Avoidance Learning | 1 | 2010 | 65 | 0.310 |
Why?
| | Neuropsychological Tests | 3 | 2025 | 1137 | 0.310 |
Why?
| | Retrospective Studies | 6 | 2025 | 17101 | 0.290 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1416 | 0.290 |
Why?
| | Cognitive Dysfunction | 3 | 2024 | 464 | 0.290 |
Why?
| | Morphine Dependence | 2 | 2005 | 5 | 0.290 |
Why?
| | Dietary Fats | 1 | 2011 | 315 | 0.290 |
Why?
| | Time Factors | 8 | 2025 | 7184 | 0.280 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2008 | 108 | 0.280 |
Why?
| | Taste | 1 | 2010 | 240 | 0.260 |
Why?
| | Cytokines | 2 | 2026 | 2065 | 0.260 |
Why?
| | Mesencephalon | 1 | 2007 | 65 | 0.260 |
Why?
| | Analysis of Variance | 5 | 2011 | 1311 | 0.250 |
Why?
| | Drug Administration Schedule | 4 | 2011 | 783 | 0.250 |
Why?
| | Receptors, Nicotinic | 2 | 2008 | 323 | 0.240 |
Why?
| | Epilepsy, Reflex | 1 | 2026 | 2 | 0.240 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2005 | 188 | 0.240 |
Why?
| | Young Adult | 10 | 2026 | 14126 | 0.230 |
Why?
| | Mice | 5 | 2026 | 18366 | 0.230 |
Why?
| | Histamine N-Methyltransferase | 1 | 2005 | 1 | 0.230 |
Why?
| | Tacrine | 1 | 2005 | 2 | 0.230 |
Why?
| | Galantamine | 1 | 2005 | 4 | 0.230 |
Why?
| | Sex Characteristics | 1 | 2011 | 791 | 0.220 |
Why?
| | Sucrose | 3 | 2011 | 115 | 0.220 |
Why?
| | Magnetoencephalography | 2 | 2023 | 162 | 0.220 |
Why?
| | Fragile X Syndrome | 1 | 2026 | 119 | 0.220 |
Why?
| | Drug Interactions | 3 | 2020 | 401 | 0.220 |
Why?
| | Treatment Outcome | 5 | 2026 | 11699 | 0.220 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 6055 | 0.210 |
Why?
| | Diet, Ketogenic | 1 | 2024 | 38 | 0.210 |
Why?
| | Calcium Signaling | 1 | 2026 | 252 | 0.200 |
Why?
| | Eating | 3 | 2011 | 392 | 0.200 |
Why?
| | Behavior, Animal | 1 | 2007 | 520 | 0.200 |
Why?
| | Magnetic Resonance Imaging | 4 | 2025 | 3870 | 0.200 |
Why?
| | Epilepsy, Temporal Lobe | 1 | 2023 | 38 | 0.200 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2024 | 125 | 0.200 |
Why?
| | Microfilament Proteins | 1 | 2024 | 136 | 0.190 |
Why?
| | Deep Brain Stimulation | 1 | 2026 | 213 | 0.190 |
Why?
| | Diagnosis, Differential | 3 | 2024 | 1496 | 0.190 |
Why?
| | Calcium-Binding Proteins | 1 | 2024 | 220 | 0.190 |
Why?
| | Fever | 1 | 2024 | 312 | 0.180 |
Why?
| | Phenobarbital | 1 | 2022 | 20 | 0.180 |
Why?
| | Valproic Acid | 1 | 2022 | 48 | 0.180 |
Why?
| | Weight Gain | 3 | 2011 | 559 | 0.180 |
Why?
| | Quality of Life | 3 | 2025 | 3192 | 0.170 |
Why?
| | Electrodes | 1 | 2022 | 115 | 0.170 |
Why?
| | Enzyme Inhibitors | 1 | 2005 | 826 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2008 | 2032 | 0.170 |
Why?
| | Brain Injuries | 1 | 2026 | 508 | 0.170 |
Why?
| | Ipilimumab | 1 | 2021 | 40 | 0.160 |
Why?
| | Mice, Knockout | 2 | 2026 | 3125 | 0.160 |
Why?
| | Dementia | 1 | 2024 | 304 | 0.160 |
Why?
| | Technology | 1 | 2020 | 96 | 0.150 |
Why?
| | Drug Combinations | 1 | 2021 | 392 | 0.150 |
Why?
| | Drinking | 2 | 2010 | 44 | 0.150 |
Why?
| | Video Recording | 1 | 2020 | 213 | 0.150 |
Why?
| | Artificial Intelligence | 1 | 2024 | 367 | 0.150 |
Why?
| | Immunotherapy | 1 | 2024 | 657 | 0.150 |
Why?
| | Aged | 7 | 2026 | 25957 | 0.150 |
Why?
| | Pilot Projects | 2 | 2023 | 1891 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2024 | 988 | 0.140 |
Why?
| | Microglia | 1 | 2021 | 269 | 0.140 |
Why?
| | Adolescent | 5 | 2025 | 22453 | 0.130 |
Why?
| | Administration, Oral | 1 | 2020 | 848 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2020 | 548 | 0.130 |
Why?
| | Kidney | 1 | 2005 | 1496 | 0.130 |
Why?
| | Cognition | 2 | 2023 | 1269 | 0.130 |
Why?
| | Benzodiazepines | 1 | 2018 | 168 | 0.130 |
Why?
| | Awareness | 1 | 2018 | 110 | 0.130 |
Why?
| | Patient Satisfaction | 1 | 2021 | 706 | 0.120 |
Why?
| | Body Weight | 2 | 2011 | 978 | 0.120 |
Why?
| | Attitude | 1 | 2018 | 261 | 0.120 |
Why?
| | Alzheimer Disease | 1 | 2022 | 622 | 0.120 |
Why?
| | Critical Care | 1 | 2022 | 697 | 0.120 |
Why?
| | Neurofilament Proteins | 2 | 2026 | 80 | 0.110 |
Why?
| | Research Design | 1 | 2022 | 1137 | 0.110 |
Why?
| | Social Stigma | 1 | 2018 | 172 | 0.110 |
Why?
| | Referral and Consultation | 1 | 2021 | 853 | 0.110 |
Why?
| | Dermacentor | 1 | 2014 | 2 | 0.100 |
Why?
| | Microdialysis | 3 | 2011 | 56 | 0.100 |
Why?
| | Quality Improvement | 1 | 2023 | 1292 | 0.100 |
Why?
| | Plasmapheresis | 1 | 2013 | 23 | 0.100 |
Why?
| | New York | 1 | 2014 | 127 | 0.100 |
Why?
| | Inflammation | 1 | 2025 | 2880 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2021 | 1524 | 0.100 |
Why?
| | Comorbidity | 1 | 2018 | 1660 | 0.100 |
Why?
| | Electronic Health Records | 1 | 2021 | 1177 | 0.090 |
Why?
| | Aged, 80 and over | 2 | 2024 | 8282 | 0.090 |
Why?
| | Pandemics | 1 | 2021 | 1695 | 0.090 |
Why?
| | Cholesterol | 2 | 2011 | 408 | 0.090 |
Why?
| | Homovanillic Acid | 2 | 2011 | 10 | 0.090 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 2011 | 598 | 0.090 |
Why?
| | 3,4-Dihydroxyphenylacetic Acid | 2 | 2011 | 20 | 0.090 |
Why?
| | Renal Insufficiency | 1 | 2013 | 169 | 0.090 |
Why?
| | Child | 4 | 2025 | 22657 | 0.080 |
Why?
| | Cohort Studies | 2 | 2020 | 5966 | 0.080 |
Why?
| | Drinking Behavior | 1 | 2011 | 14 | 0.080 |
Why?
| | Ghrelin | 1 | 2011 | 39 | 0.080 |
Why?
| | Lithium Chloride | 1 | 2010 | 13 | 0.080 |
Why?
| | Drug Administration Routes | 2 | 2007 | 44 | 0.080 |
Why?
| | Biopsy | 1 | 2013 | 1077 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2022 | 6433 | 0.080 |
Why?
| | Biomarkers | 3 | 2026 | 4276 | 0.070 |
Why?
| | Mental Disorders | 1 | 2018 | 1172 | 0.070 |
Why?
| | Saccharin | 1 | 2008 | 9 | 0.070 |
Why?
| | Food, Formulated | 1 | 2008 | 16 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 847 | 0.070 |
Why?
| | Child, Preschool | 3 | 2024 | 11799 | 0.070 |
Why?
| | Appetite Regulation | 1 | 2008 | 32 | 0.070 |
Why?
| | Injections, Intraperitoneal | 1 | 2008 | 117 | 0.070 |
Why?
| | Animal Feed | 1 | 2008 | 54 | 0.070 |
Why?
| | Solutions | 1 | 2008 | 167 | 0.070 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2008 | 59 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2118 | 0.070 |
Why?
| | Energy Intake | 1 | 2011 | 500 | 0.070 |
Why?
| | Sodium Chloride | 1 | 2008 | 142 | 0.070 |
Why?
| | Grooming | 1 | 2007 | 9 | 0.070 |
Why?
| | Methamphetamine | 1 | 2008 | 71 | 0.060 |
Why?
| | Nicotinic Agonists | 1 | 2008 | 137 | 0.060 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2026 | 9 | 0.060 |
Why?
| | United States | 1 | 2024 | 16000 | 0.060 |
Why?
| | Cocaine | 1 | 2008 | 161 | 0.060 |
Why?
| | Inositol 1,4,5-Trisphosphate Receptors | 1 | 2026 | 29 | 0.060 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2026 | 73 | 0.060 |
Why?
| | Locus Coeruleus | 1 | 2005 | 25 | 0.060 |
Why?
| | Acute Kidney Injury | 1 | 2013 | 868 | 0.060 |
Why?
| | Mecamylamine | 1 | 2005 | 7 | 0.060 |
Why?
| | Nicotine | 1 | 2008 | 332 | 0.060 |
Why?
| | Dextromethorphan | 1 | 2005 | 24 | 0.060 |
Why?
| | Bupropion | 1 | 2005 | 47 | 0.050 |
Why?
| | Cimetidine | 1 | 2004 | 12 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2023 | 3416 | 0.050 |
Why?
| | DNA, Complementary | 1 | 2005 | 277 | 0.050 |
Why?
| | Acoustic Stimulation | 1 | 2026 | 334 | 0.050 |
Why?
| | Seizures, Febrile | 1 | 2024 | 23 | 0.050 |
Why?
| | Cloning, Molecular | 1 | 2005 | 541 | 0.050 |
Why?
| | Brain Stem | 1 | 2004 | 96 | 0.050 |
Why?
| | Blood Glucose | 2 | 2011 | 2333 | 0.050 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1048 | 0.050 |
Why?
| | Prospective Studies | 2 | 2026 | 8000 | 0.050 |
Why?
| | Rituximab | 1 | 2024 | 210 | 0.050 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2004 | 124 | 0.050 |
Why?
| | Epileptic Syndromes | 1 | 2024 | 96 | 0.050 |
Why?
| | Feeding Behavior | 1 | 2008 | 685 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 722 | 0.050 |
Why?
| | ROC Curve | 1 | 2024 | 615 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2023 | 103 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2005 | 1048 | 0.040 |
Why?
| | Acute Disease | 1 | 2005 | 1031 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2005 | 1371 | 0.040 |
Why?
| | Brain Mapping | 1 | 2004 | 537 | 0.040 |
Why?
| | Disease Management | 1 | 2024 | 647 | 0.040 |
Why?
| | Risk Factors | 1 | 2013 | 10797 | 0.040 |
Why?
| | Injections, Intraventricular | 2 | 2011 | 58 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2023 | 1035 | 0.030 |
Why?
| | Attention | 1 | 2020 | 458 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2026 | 5417 | 0.030 |
Why?
| | Critical Illness | 1 | 2022 | 892 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2026 | 5873 | 0.030 |
Why?
| | Disease Progression | 1 | 2022 | 2852 | 0.030 |
Why?
| | Triglycerides | 1 | 2011 | 521 | 0.020 |
Why?
| | Extracellular Fluid | 1 | 2008 | 37 | 0.020 |
Why?
| | Electrochemistry | 1 | 2008 | 74 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2011 | 653 | 0.010 |
Why?
| | Injections, Spinal | 1 | 2004 | 121 | 0.010 |
Why?
| | Naltrexone | 1 | 2005 | 118 | 0.010 |
Why?
| | Narcotic Antagonists | 1 | 2005 | 206 | 0.010 |
Why?
| | Spinal Cord | 1 | 2004 | 382 | 0.010 |
Why?
|
|
Taraschenko's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|